Article    Table of Contents                    Full Text of this article Free  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Gradishar, W. J.    Abrams, J. S.    Related Articles in PubMed    PubMed Citation    PubMed

PERSPECTIVE

High-Dose Chemotherapy for Breast Cancer

William J. Gradishar, MD; Martin S. Tallman, MD; and Jeffrey S. Abrams, MD

1 October 1996 | Volume 125 Issue 7 | Pages 599-604

The role of high-dose chemotherapy in the management of women with breast cancer remains one of the most controversial issues in oncology. During the past decade, numerous pilot studies have shown the feasibility of administering high-dose chemotherapy followed by autologous bone marrow transplantation or peripheral blood stem-cell transplantation (referred to as high-dose chemotherapy) to women with metastatic disease. However, it appears that survival improves in few treated patients. This treatment strategy is now being evaluated in the adjuvant setting in patients who are at high risk for developing recurrent disease. The National Cancer Institute has selected two randomized, adjuvant breast cancer trials for its High-Priority Clinical Trials Program. These trials are comparing conventional-dose chemotherapy with high-dose chemotherapy in patients in the early stages of breast cancer who are at high risk for disease recurrence.

This paper focuses on the rationale for the randomized studies evaluating adjuvant high-dose chemotherapy in the early stages of breast cancer and reviews the efforts to overcome physician and patient biases so that the trials can be completed.

Author and Article Information

From Northwestern University, Chicago, Illinois, and the National Cancer Institute, Bethesda, Maryland.
Acknowledgment: The authors thank Vicky James for assistance in preparing this manuscript.
Grant Support: By 17-96-2-6013 from the Department of Defense (Dr. Gradishar) and R21 CA 64487-01 from the National Cancer Institute.
Requests for Reprints: William J. Gradishar, MD, Robert H. Lurie Cancer Center, Northwestern University, 233 East Erie, Suite 700, Chicago, IL 60611.
Current Author Addresses: Drs. Gradishar and Tallman: Northwestern University, 233 East Erie, Suite 700, Chicago, IL 60611.

This article has been cited by other articles:

				A. R. Zander, C. Schmoor, N. Kroger, W. Kruger, V. Mobus, N. Frickhofen, B. Metzner, W. E. Berdel, M. Koenigsmann, E. Thiel, et al. Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up Ann. Onc., June 1, 2008; 19(6): 1082 - 1089. [Abstract] [Full Text] [PDF]

				A.R. Zander, N. Kroger, C. Schmoor, W. Kruger, V. Mobus, N. Frickhofen, B. Metzner, W. Schultze, W.E. Berdel, M. Koenigsmann, et al. High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Support Compared With Standard-Dose Chemotherapy in Breast Cancer Patients With 10 or More Positive Lymph Nodes: First Results of a Randomized Trial J. Clin. Oncol., June 15, 2004; 22(12): 2273 - 2283. [Abstract] [Full Text] [PDF]

				M. S. Tallman, R. Gray, N. J. Robert, C. F. LeMaistre, C. K. Osborne, W. P. Vaughan, W. J. Gradishar, T. M. Pisansky, J. Fetting, E. Paietta, et al. Conventional Adjuvant Chemotherapy with or without High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in High-Risk Breast Cancer N. Engl. J. Med., July 3, 2003; 349(1): 17 - 26. [Abstract] [Full Text] [PDF]

				M. M. Mello and T. A. Brennan The Controversy Over High-Dose Chemotherapy With Autologous Bone Marrow Transplant For Breast Cancer Health Aff., September 1, 2001; 20(5): 101 - 117. [Abstract] [Full Text] [PDF]

				S. E. Braun, K. Chen, R. G. Foster, C. H. Kim, R. Hromas, M. H. Kaplan, H. E. Broxmeyer, and K. Cornetta The CC Chemokine CK{beta}-11/MIP-3{beta}/ELC/Exodus 3 Mediates Tumor Rejection of Murine Breast Cancer Cells Through NK Cells J. Immunol., April 15, 2000; 164(8): 4025 - 4031. [Abstract] [Full Text] [PDF]

				P. A. Rowlings, S. F. Williams, K. H. Antman, K. K. Fields, J. W. Fay, E. Reed, C. J. Pelz, J. P. Klein, K. A. Sobocinski, M. J. Kennedy, et al. Factors Correlated With Progression-Free Survival After High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Metastatic Breast Cancer JAMA, October 13, 1999; 282(14): 1335 - 1343. [Abstract] [Full Text] [PDF]

				C.H. Weaver, W. West, L. Schwartzberg, R. Birch, and C.D. Buckner The Rationale for Performing Autologous Peripheral Blood Stem Cell Transplants in Community Cancer Centers Oncologist, October 1, 1998; 3(5): 346 - 353. [Abstract] [Full Text]

				S. Mach-Pascual, R. D. Legare, D. Lu, M. Kroon, D. Neuberg, R. Tantravahi, R. M. Stone, A. S. Freedman, L. M. Nadler, J. G. Gribben, et al. Predictive Value of Clonality Assays in Patients With Non-Hodgkin's Lymphoma Undergoing Autologous Bone Marrow Transplant: A Single Institution Study Blood, June 15, 1998; 91(12): 4496 - 4503. [Abstract] [Full Text] [PDF]